MedPath

Optimization of the Preservation of Muscle Mass and / or Its Recovery by a Protein-energy Chrononutrition Approach Dissociated From Meals

Not Applicable
Terminated
Conditions
Undernutrition
Interventions
Dietary Supplement: Protein
Dietary Supplement: Protein and Carbohydrate
Registration Number
NCT03867006
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Muscle wasting has a multifactorial origin, including decreased physical activity, malnutrition, loss of post-incident muscle recovery abilities, and decreased ability to regenerate muscle. Among the strategies tested to improve the production of proteins and thus muscle is the supplementation of whey proteins. However this strategy does not seem sufficient and optimal to avoid muscle wasting and it must be complemented by a complementary action.

Muscle protein degradation also occurs during the nocturnal fasting periods to provide amino acids for energy purposes and to produce glucose, essential for vital organs. The preservation of the benefit of whey intake during meals could therefore be optimized by reducing the use of muscle proteins for energy purposes during the night.

Detailed Description

In this study, three arms will be studied for 3 months: 1 control group, 1 group with whey supplementation at lunch, and 1 group with whey supplementation at lunch and an energy bolus before bedtime. Actions include weight and body composition monitoring, nutritional status and muscle function, as well as mechanistic.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Resident on the Accommodation Establishments for Dependent Elderly Persons on the Mutuality of Loire, France

  • Risk of undernutrition or moderate undernutrition with one of the following criteria :

    • Either 5-10% of weight loss in 1 month or 10-15% in 6 months.
    • Or Body Mass Index (BMI) between 16 and 21
    • Or Albumin levels between 30 and 35 g/L
    • Or global Mini Nutritional Assessment (MNA) test between 17 and 23.5
    • Or Short Emergency Geriatric Assessment (SEGA) Score >8
Exclusion Criteria
  • Sub-acute pathology (flu, gastroenteritis, bacterial infections ...) or trauma (fracture, surgery ...) in the 30 days prior to inclusion.
  • Hepatocellular insufficiency
  • Heart failure with decompensation
  • Severe dementia,
  • Insulin-treated diabetes
  • Renal insufficiency (clearance <30 ml / min)
  • Long-term cortico-therapy
  • Cancer undergoing chemotherapy treatment or/and radiotherapy
  • Gastrointestinal pathology,
  • Diet incompatible with the nutritional protocol (intolerance to milk or lactose, vegetarians, vegans, ...)
  • Motor disability leading to the impossibility of doing muscle function tests.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
protein groupProteinPatients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
protein and carbohydrates groupProtein and CarbohydratePatients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
Primary Outcome Measures
NameTimeMethod
Appendicular lean body mass (gramme)Days 0 and 90

Comparison appendicular lean body mass between the day of inclusion and 90 days after. It is measuring by Dual Energy X-ray Absorptiometry (DEXA).

Secondary Outcome Measures
NameTimeMethod
Inflammatory statusDays 0, 45 and 90

Analysis of inflammatory status by blood sample results. C-reactive protein (CRP), Interleukin 6 (IL-6), Tumor necrosis factor (TNFα), monocyte chemoattractant protein 1 (MCP1)

Plasma albumin level (g/l)Days 0, 45 and 90

blood sample.

Get up-and-go test (s)Days 0 and 90

Analysis of muscle function tests.

Frailty screening toolDays 0 and 90

Determination of fragility status. 3 status : Dependent, Fragile, Robust

6 minutes walk test (m)Days 0 and 90

Analysis of muscle function tests.

Profiles of the differential expression of potentials biomarkersDays 0, 45 and 90

Analysis of profiles of the differential expression of potentials biomarkers by results of blood sample with heparin, urine sample and white blood cells.

microbiotaDays 0 and 90

Analysis of microbiota by stool sample results.

total body compositionDays 0, 45 and 90

Correlation between Dual Energy X-ray Absorptiometry (DEXA) results and bioelectrical impedance analysis results to determine total body composition.

Mini Nutritional Assessment scoreDays 0 and 90

Determine nutritional status. Score : 0-30

Hand Grip test (N)Days 0 and 90

Analysis of muscle function tests.

Maximal voluntary contraction of quadriceps (N)Days 0 and 90

Analysis of muscle function tests.

Trial Locations

Locations (3)

EHPAD Cité des Aînés

🇫🇷

Saint-Étienne, France

EHPAD La Cerisaie

🇫🇷

Saint-Étienne, France

EHPAD Le Soleil

🇫🇷

Saint-Étienne, France

© Copyright 2025. All Rights Reserved by MedPath